AZD2624 Multiple Ascending Dose Study in Japan
Summary
This multiple ascending dose study will evaluate safety and tolerability after repeated ascending doses of AZD2624
Study Design
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Conditions
Healthy
Intervention
AZD2624, Placebo
Location
Research Site
Kanagawa
Japan
Status
Completed
Source
AstraZeneca
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00696865
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Therapeutic Misconception
Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.
Placebo Effect
An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.
Clinical Trials
None
PubMed Articles
Placebo interventions, placebo effects and clinical practice.
This article reviews the role of placebo interventions and placebo effects in clinical practice. We first describe the relevance of different perspectives among scientists, physicians and patients on...
Placebo expectations and the detection of somatic information.
In a laboratory study we examined the hypothesis that placebo expectations enhance the initial identification of placebo-relevant sensations over placebo-irrelevant sensations. Participants (N = 102...
The silent healer: The role of communication in placebo effects.
Placebo effects have an ambiguous reputation, as they are associated with sham treatment and deceit on the one hand and as interesting phenomena, which might be clinically relevant on the other. The g...
The placebo response in clinical trials: more questions than answers.
Meta-analyses and re-analyses of trial data have not been able to answer some of the essential questions that would allow prediction of placebo responses in clinical trials. We will confront these que...
The calculation of antidepressant-placebo difference (50% - 30% = 20%) in drug trials is based on the postulate that all placebo responders should be 'automatically' antidepressant responders,...
